<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932475</url>
  </required_header>
  <id_info>
    <org_study_id>15-3235</org_study_id>
    <secondary_id>1R01HD086139-01A1</secondary_id>
    <nct_id>NCT02932475</nct_id>
  </id_info>
  <brief_title>Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)</brief_title>
  <acronym>MOMPOD</acronym>
  <official_title>Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The objective of this proposal is to study the safety and efficacy of metformin
      added to insulin for treatment of type 2 diabetes mellitus (T2DM) among pregnant women.

      Participants: 1200 pregnant women with type 2 diabetes complicating pregnancy from 10 U.S.
      clinical centers

      Procedures (methods): Pregnant women with T2DM between 10 weeks and 20 weeks 6 days and a
      singleton fetus will be randomized to insulin/placebo versus insulin/metformin. Primary
      outcome is composite adverse neonatal outcome (clinically relevant hypoglycemia, birth
      trauma, hyperbilirubinemia, stillbirth/neonatal death). Study visits monthly at clinical
      visits; blood draw at 24-30 weeks. Maternal and infant outcomes will be chart abstracted.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite adverse neonatal outcome</measure>
    <time_frame>An average of 48 hours for term infants and 30 days for preterm infants</time_frame>
    <description>Capillary blood glucose level of &lt; 30 mg/dL or capillary blood glucose requiring medical treatment, or
Birth trauma (umbilical cord artery pH &lt; 7.0 or shoulder dystocia with brachial plexus injury), or
Hyperbilirubinemia requiring phototherapy, or
Deliver &lt; 37 weeks' gestation, or
Miscarry, are stillborn, experience a neonatal demise, or
Large for gestational age infant (birth weight &gt; 90th percentile for gestational age), or
Small for gestational age infant (birth weight &lt; 10th percentile for gestational age) or low birth weight (&lt; 2500 gm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal safety</measure>
    <time_frame>An average of 48 hours following delivery</time_frame>
    <description>Adverse maternal outcomes, e.g. death, diabetic ketoacidosis, hypoglycemia requiring medical therapy, ICU admission/intubation, renal failure
• Maternal obstetrical complications, e.g. placental abruption, preeclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant fat mass</measure>
    <time_frame>Within 72 hrs of birth</time_frame>
    <description>Percent neonatal fat mass measured by skin-fold thickness (anthropometrics) measured at flank, biceps and sub scapular</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal side effects</measure>
    <time_frame>Throughout study until delivery at 40 weeks gestation</time_frame>
    <description>Maternal clinically relevant hypoglycemia defined as capillary blood glucose &lt; 60 or &lt; 80 with symptoms
• Maternal side effects such as nausea, vomiting, diarrhea that cannot be managed with oral medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Diabetes</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 1000 mg twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo, identical to Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg twice a day</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Glumetza</other_name>
    <other_name>Fortamet</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Riomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Delivered to match active drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age 18-45 years

          -  Singleton pregnancy with no known fetal anomalies

          -  Gestational age between 10weeks 0 days and 20 weeks 6 days by menstrual dating
             confirmed by ultrasound, or ultrasound alone

          -  Clinical diagnosis of preexisting T2DM requiring medical treatment (oral agent or
             insulin)

          -  Clinical diagnosis of diabetes diagnosed between 10 weeks and &lt; 20 weeks 6 days
             gestation

          -  Willing to start insulin therapy and discontinue oral hypoglycemic pills other than
             study pills

          -  Able to swallow pills

        Exclusion Criteria:

          -  Clinical diagnosis of pre-existing renal disease, defined as creatinine &gt; 1.5 mg/dL

          -  Clinical history of lactic acidosis

          -  Known allergy to metformin

          -  Participation in another study that could affect primary outcome

          -  Delivery planned at non-MOMPOD study locations

          -  Unwillingness to use insulin treatment or follow prenatal care doctor's instructions
             for insulin and blood glucose monitoring
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Boggess, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amber Irvins</last_name>
    <phone>(919) 843-4420</phone>
    <email>amber_irvins@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Dorman</last_name>
    <phone>(984) 974-9012</phone>
    <email>kdorman@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lori Harper, MD</last_name>
      <phone>205-934-5611</phone>
      <email>lmharper@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gladys Ramos, MD</last_name>
      <phone>619-543-6906</phone>
      <email>gramos@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>38677</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kedra Wallace, MD</last_name>
      <phone>601-984-5396</phone>
      <email>kwallace2@umc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Wapner, MD</last_name>
      <phone>212-305-1521</phone>
      <email>rw2191@columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Boggess, MD</last_name>
      <phone>919-966-1601</phone>
      <email>kboggess@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Dorman</last_name>
      <phone>984-974-9012</phone>
      <email>kdorman@med.unc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Landon, MD</last_name>
      <phone>614-293-8513</phone>
      <email>mark.landon@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celeste Durswald, MD</last_name>
      <phone>215-615-3817</phone>
      <email>celeste.durnwald@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gayle Olson, MD</last_name>
      <phone>409-747-4905</phone>
      <email>golson@utmb.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffie Refuerzo</last_name>
      <phone>713-500-6416</phone>
      <email>jerrie.s.refuerzo@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Varner</last_name>
      <phone>801-581-4173</phone>
      <email>michael.varner@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

